We are talking about GLP-1 (glucagon-like peptide; this group includes the drug semaglutide Ozempic produced by Novo Nordisk, so popular among Hollywood stars), as well as SGLT-2 (a group of gliflozins that have a hypoglycemic effect). .
Already in 2027, an innovative combination of GLP-1 and SGLT-2 is planned to be introduced on the Russian market: the drug is intended for patients with type 2 diabetes mellitus and other metabolic disorders. And in 2029 the production of the first domestic drug GLP-1 will begin: it is known that it can be used to treat not only diabetes, but also polyneuropathy.
“GLP-1 agonists are a modern class of glucose-lowering medications that can provide reliable glycemic control, weight loss, and also reduce the risks of cardiovascular complications and renal dysfunction. They are widely used for the treatment of metabolic disorders in Europe and the rest of the world. Today, sales of GLP-1 account for 55% of all global sales of drugs for the treatment of type 2 diabetes. According to Bloomberg, sales of GLP agonists -1 will reach 800 billion dollars a year in 2030,” explained Sechenov University.
In Russia, endocrinologists also successfully used semaglutide and other drugs from the same group, supplied from abroad. However, in recent years the situation has become more complicated. Novo Nordisk has maintained the production and supply of modern insulins in Russia, including special doses for children (the company’s products now account for about 30% of all insulins in our market). But supplies of semaglutide were reduced and then stopped entirely.
According to official data, in Russia there are more than 4.7 million registered patients with type 2 diabetes mellitus and their number is increasing by 6% annually. And the number of obese Russians (body mass index over 30), according to official statistics, exceeds two million people. But at the SPIEF session dedicated to this problem, both the country’s leading endocrinologists and representatives of the Ministry of Health said that official data are dramatically underestimated and, in fact, almost every third person in Russia has obesity to some degree or another. other. Although patients and even some doctors underestimate the seriousness of the situation and do not consider obesity an endocrine disease, 420 thousand new patients are diagnosed with this disease each year.
The emergence of domestic analogues of GLP-1 and innovative molecules of this class will significantly improve the quality of medical care for diabetics and overweight and obese people. And the entry into the market of domestic SGLT-2 inhibitors is important for patients who have heart failure or chronic kidney disease as a complication.
“Today, Sechenov University has built a complete translational cycle of drug development in accordance with the highest industry standards,” said the rector of the First Moscow State Medical University and academician of the Russian Academy of Sciences , Pyotr Glybochko. cooperate with the leaders of the Russian pharmaceutical market, carrying out both contract research and joint projects. Now one of our main tasks, as a university that is transforming into a world-class scientific research medical university, together with our partners, is to create innovative medicines. , including for the treatment of diabetes.
Today, most GLP-1 drugs are produced in injectable form: they must be administered by injections. Russian scientists set out to develop a drug that should be taken orally once a day. Of course, this is important to improve the quality of life of patients.
The combination of drugs of the GLP-1 class and SGLT-2 inhibitors will also make it possible to change the treatment regimen and instead of two different drugs, the treatment regimen will include one modern drug.
